Possibility of Heightened Risk of Resistant TB Following Drug Treatment of Latent TB Owing to Lack of Confirmatory Tests to Determine Their Cure and Diagnosis

Why It Matters

Unverified LTBI treatment could seed drug‑resistant TB, undermining global eradication goals and increasing public‑health costs.

Key Takeaways

• LTBI treatment lacks reliable cure verification tests
• TST and IGRA cannot distinguish active from latent TB
• No culture data prevents resistance monitoring during LTBI therapy
• Inadequate monitoring may foster drug‑resistant TB strains
• Nutrition and education proposed to boost immunity alongside therapy

Pulse Analysis

The global fight against tuberculosis hinges not only on treating active disease but also on preventing its emergence from latent infections. While the World Health Organization endorses short‑course regimens such as weekly rifapentine‑isoniazid, the absence of a definitive endpoint test means clinicians cannot confirm bacterial eradication. This diagnostic blind spot is especially problematic in high‑risk populations—people with HIV, diabetes, or living in crowded settings—where a missed resistant strain can quickly spread.

Scientific consensus highlights that tuberculin skin tests and interferon‑gamma release assays, the mainstays for LTBI detection, provide only indirect evidence of immune sensitisation. Their inability to differentiate between dormant bacilli and low‑level active replication leaves treatment decisions vulnerable to error. Moreover, without culture and susceptibility testing, health systems cannot track emerging resistance patterns, raising the specter of multidrug‑resistant TB arising from prophylactic courses that may be sub‑optimal or prematurely halted.

Policy makers and clinicians are therefore urged to adopt a dual‑track approach: maintain evidence‑based chemoprophylaxis while bolstering host defenses through nutrition and targeted education. Distributing protein‑rich foods like peanuts and chickpeas, coupled with IEC campaigns, can enhance immune resilience, potentially reducing reliance on imperfect drug regimens. Integrating these complementary strategies could mitigate the risk of drug‑resistant TB and sustain progress toward the WHO’s End TB targets.